AI Pharma Breakthrough: 12 Biotechs Poised to Disrupt the Trillion-Dollar Drug Market, Per Labiotech.eu

According toGrand View Research Data,2022 The global AI-driven drug discovery market size in year11Billion US dollars, expected2023 toCAGR by 2030(CAGR) Will Reach29.6%。

Recently, the top biotechnology website in EuropeLabiotech.euThe 12 most noteworthy companies in the AI drug discovery field have been selected, as they have made significant technological advancements.

Anima Biotech 

• Technology:mRNABiological Regulator

• Disease Areas: Immunology, Oncology, and Neuroscience

• Latest News: Promising Preclinical Data Released for Key Drug Treating Pulmonary Fibrosis 

Anima Biotech TheAI Drug discovery technology withmRNA Lightning.AI Platform as the foundation, which can image hundreds of cellular pathways in both healthy and diseased cells to train for specific diseases.AI Models utilize neural networks to help distinguish between healthy and diseased cells and identify dysregulated pathways. These pathways are then analyzed to discover new targets supported by experimental validation.

CompanyCurrently, there is20A number of preclinical candidate drugs are being evaluated for immunology, oncology, and neuroscience indications, with the most advanced candidate drug intended for the treatment of pulmonary fibrosis. The company2024 Year2It was announced in the month that the candidate drug has shown good preclinical results and may open new avenues for the treatment of patients with idiopathic pulmonary fibrosis.

ThisAI pharmaceutical companies have also established ongoing collaborations with multiple giants.Anima Biotech was initially2018 Year of collaboration with Eli Lilly and Company,2021 Years of collaboration with Takeda, the most recent one being2023 Years of collaboration with AbbVie, aiming to discover and develop targets in oncology and immunology.mRNA Biological Modulators.

Insilico Medicine

• Technology: Small Molecule Inhibitors

• Disease Area: Fibrosis

• Latest News:ERound of Financing1.1Billion US dollars

Insilico MedicineCommitted to using artificial intelligence at every step of drug development to significantly reduce the time and cost required to bring life-saving drugs to patients. To achieve this goal, the company uses next-generation AI systems to connect biology, chemistry, and clinical trial analysis. Its fully integrated drug discovery suitePharma.AI IncludingPandaOmics(Used for discovering and prioritizing new targets),Chemistry42(Used for generating new molecules) andInClinico(Used for designing and predicting clinical trials).

2023Year6Month,Insilico Small Molecule Inhibitor Candidate for the Treatment of Idiopathic Pulmonary FibrosisINS018_055 Becoming the first to enter2 The full text of the clinical trial period isAI Discovery andAI Designed Drugs, which is an important milestone in the industry. The company then2024 Year6 Announced in the month, the candidate drug has been completed in China2a Patient recruitment for the phase study. ThisAI The company has two other drugs in the clinical stage, partially byAI Generation. A treatment forCOVID-19, and the other is for the treatment of solid tumors.

It is worth mentioning that,2022Year11Month,Insilico MedicineSigned a deal worth up to12Hundred MillionMajor cooperation agreement in US dollars. The agreement states that Sanofi will utilize Insilico.ThePharma.AIIdentify disease targets, generate new molecular data, and predict clinical trial outcomes to advance candidate drugs for up to six new targets.

Meanwhile, earlier this month, Insilico MedicineObtained1.1 Billion US dollarsE Round of financing, this funding will be used to advance its drug development pipeline andAI Platform Development.

Atomwise 

• Technology:TYK2Inhibitor

• Disease Area: Autoimmune and Autoinflammatory Diseases

• Latest News: The published results demonstrate AtomNet Drug Discovery Capabilities

Atomwise Anima Biotech Inc. is harnessing the power of AI in an attempt to revolutionize the discovery of small molecule drugs. The company aims to address the most challenging and seemingly impossible targets while streamlining the drug discovery process, providing drug developers with more opportunities to achieve their goals.

Atomwise The drug discovery method shifts the drug discovery model from serendipitous discovery to structure-based search, making the drug discovery process more rational, effective, and efficient. The company'sAtomNet The platform combines deep learning for structure-based drug design, enabling rapid and AI-driven searches within its proprietary library of over three trillion synthesizable compounds.

2024 Year4 Month, thisAI A drug research and development company released a318 The results of the target study emphasizeAtomNet Is a viable alternative to high-throughput screening, whereAI Platform evaluated in the study318 Identified from the target235 A novel structural target.

This is Atomwise One of the largest deals was a strategic multi-target research collaboration agreement signed between the company and pharmaceutical giant Sanofi, utilizing its...AtomNet The platform conducts computational discovery and research on up to five drug targets.

At the same time,2023 Year10 Month, the company also announced its firstAI Nomination of Driver Candidate Drugs — An Orally Bioavailable AllostericTYK2 Inhibitor.TYK2 Is a key mediator in cytokine signaling pathways associated with various immune-mediated inflammatory diseases. By modulatingTYK2 Pathway, the candidate drug has the potential to treat various autoimmune and autoinflammatory diseases, including inflammatory bowel disease, systemic lupus erythematosus, psoriasis, and psoriatic arthritis.

Atomwise The current top priority is to advance the candidate drug into human trials.

BPGbio

• Technology: Drugs-Lipid Complex Nanodispersion

• Disease Areas: Oncology, Neurology, and Rare Diseases

• Latest News: Establishment with the University of Oxford 5 Year Partnership to Jointly Develop New Protein Degradation Technology

BPGbio ByBioTech Breakthrough AwardsRated as2024 "Biotechnology of the Year"AI Company", itsAI The platform is namedNAi Interrogative Biology, utilizing one of the largest non-government biobanks in the world, with over100,000 A patient sample with clinical annotations and multi-omics annotations. The platform is driven by causality.AI And Oak Ridge National Laboratory, the world's fastest supercomputerFrontier Providing support to accelerate the identification of novel drug targets and biomarkers, enablingBPGbio Can advance the treatment of major diseases.

In 2023 Acquisition of Boston Biotech Company in [Year]BERG All assets after,BPGbio Now has a series of late-stage clinical assets in the fields of oncology, rare diseases, and neurology. Its leading assetBPM31510 Is a substance containing ubiquinone(CoQ10) Drugs-Lipid-combined nanodispersions are currently undergoing testing for topical, intravenous, and oral formulations.ViaBPGbio TheAI Platform validation,BPM31510 Induction of the tumor microenvironment by modulating mitochondrial oxidative phosphorylation in invasive tumors(TME) The hallmark shift, leading to cancer cell death. Moreover, in many mitochondrial diseases, restoringCoQ10 Levels can overcome the effects of genetic mutations that cause mitochondrial dysfunction.

BPM31510 The intravenous formulation is currently undergoing trials for glioblastoma multiforme.(GBM) And pancreatic cancer2 Phase trial. The drug has been approved by the U.S. Food and Drug Administration(FDA) Orphan drug designation for these two indications. Meanwhile, this topical formulation has recently also received orphan drug designation for Epidermolysis Bullosa, as well as for primary coenzyme.Q10 Qualification for Rare Pediatric Disease Designation for Deficiency.

2024 Year10 Month,BPGbioA deal has been reached with the University of Oxford in the UK for a period of5 Years of collaboration, focusing on advancing novel protein degradation technologies, particularly in oncology and the central nervous system.(CNS) In the field of diseases, the goal is to open up new treatment avenues for diseases with limited therapeutic options. This is the mission of this company.AI One of the numerous partnerships established by pharmaceutical research and development companies with academic institutions and healthcare organizations. Moreover, it also promotesBERG Partnerships have been established with companies such as AstraZeneca and Boehringer Ingelheim.

Cradle Bio 

• Key Areas: Therapeutics, Diagnostics, Food, Chemicals, and Agriculture

• Main Partners: Novo Nordisk, Johnson & Johnson,Grifols AndTwist Biosciences

• Latest News:B Round of Financing7300 "Million USD $"

Cradle Bio Using GenerativeAI Helping biologists design improved proteins and accelerate R&D, making it easier, faster, and more cost-effective to create bio-based products for therapeutics, diagnostics, food, chemicals, and agriculture. The company'sAI The model is based on billions of protein sequences andCradle Data generated from our own wet lab for training.

Cradle Is a platform provider that collaborates with biotechnology and pharmaceutical companies to accelerate protein engineering. The company has partnered with Novo Nordisk., Johnson & Johnson、Grifols AndTwist Biosciences ...has established partnerships with major industry players to help them improve and optimize proteins for various applications. The company is working on multiple projects focused on designing various protein forms, including enzymes, vaccines, peptides, and antibodies, covering a wide range of desired protein characteristics such as stability, expression, activity, binding affinity, and specificity.

2024 Year11 Month,CradleInB Raised in the round of financing7300 Million USD, to help the company accelerate the adoption of AI-driven protein engineering. This funding brings the total amount raised by the company to date to over1 Billion USD.

Iktos 

• Technology: Small Molecules 

• Disease Areas: Inflammation and Autoimmune Diseases, Oncology, and Obesity

• Latest News: From EIC Accelerator Obtain250 Million Euros Funding

IktosHeadquartered in Paris, the company is leveraging artificial intelligence and robotic synthesis automation technology for drug discovery and design, using this technology to rapidly identify small molecules that can become clinical candidates. By utilizing artificial intelligence,Iktos Aiming to accelerate the drug discovery process while increasing the success rate of candidate drugs entering clinical development.Iktos Has been carried out in collaboration with Johnson & Johnson, Merck, Pfizer, Servier, and other companies.50 Multiple academic and industrial collaborations have validated this approach.

The company has various artificial intelligence technologies to assist in the discovery process. These technologies include:Makya, a generative artificial intelligence that can generate optimal molecules through computers;Spaya, a retrosynthesis AI platform that processes molecules to determine withIktos Robot-compatible synthetic route; andIlaka, an "orchestrated" artificial intelligence platform that can take over the entire workflow, from ordering raw materials to overseeing synthesis activities, and directing the company's robots in chemical reactions. As a result, the company currently has a pipeline focused on providing preclinical candidates for inflammation and autoimmune diseases, oncology, and obesity.

2023 Year3 In the month, the company announced that it has completed1550 Million EurosA Round of financing, enabling it to further develop itsAI And drug discovery capabilities, expanding its existingSaaS Software products, and launchIktos Robotics——An end-to-end drug discovery platform that combinesAI And chemical synthesis automation can significantly accelerate the drug discovery timeline.

Recently,2025 Year2 Month,IktosFrom the European Innovation Council(EIC) The accelerator has been acquired.250 Million euros in funding to advance itsAI And robot technology. In addition, this year1 Month, the company andCube Biotech Signed a small moleculeAI Drug Research and Development Cooperation Agreement. This cooperation will utilizeIktos TheAI Platform andCube Biotech Advanced protein technology to develop novel agonists for the amylin receptor.

insitro

• Disease Area: Neuroscience and Metabolic Diseases

• Recent Financing:C Round of Financing4 Billion USD

• Latest News: Collaborating with Eli Lilly and Company to advance, including MASLD New therapies for metabolic diseases, including

By generating high-throughput functional genomic datasets consistent with patient data and interpreting these datasets through novel machine learning methods,insitro A predictive model has been established that can accelerate target selection and the design of effective therapies. This AI-assisted drug discovery...insitro The product line has laid a foundation, including candidate drugs in the fields of neuroscience and metabolic diseases, which are being advanced both internally and through strategic partnerships.

insitro To date, multiple partnerships have been established.2018 Not long after its establishment in the year, the company collaborated withGileadEstablished a partnership to discover and develop non-alcoholic steatohepatitis (NASH)(NASH) New therapy. Subsequently, in2020 In that year, the company collaborated with Bristol-Myers Squibb.(BMS) Signed an agreement to discover Amyotrophic Lateral Sclerosis(ALS) New Therapy - As part of this agreement,insitroLast year12 Month Obtained2500 Million-dollar milestone payments for achieving discovery milestones and selectionALS The first new target. Recently,insitroWithEli LillyCooperation, according toinsitro Using the company's basedAI/ML The platform-identified targets are advancing new therapies for metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH).(MASLD)。

In terms of financing outside of these collaborations,insitro Still2021 Achieved impressive success in4 Billion US dollarsC Round of financing, used to further expand the company's platform capabilities and channels.

Isomorphic Labs 

• Drug R&D Collaboration: Eli Lilly and Novartis 

• Recent Achievements: In Collaboration with GoogleDeepMindJoint DevelopmentAlphaFold3

• Recent News: Expansion of the Scope of the Small Molecule Drug Discovery Agreement with Novartis 

As a renowned artificial intelligence research laboratory Google Deepmind , a sister company,Isomorphic Labs Dedicated to developing cutting-edge computational technologies in areas such as deep learning, reinforcement learning, active learning, and representation learning to address some of the most challenging issues in drug discovery and some of the toughest scientific problems in today's biology, chemistry, and medical research.

The company helps Google DeepMindDeveloped an Artificial Intelligence Model Widely PraisedAlphaFold3, this model can accurately predict protein3D Structure. This technology has been hailed as a game-changer in the field of drug discovery, as it has the potential to allow researchers to identify promising drug candidates faster and more accurately than current methods, especially since last year.11 Two months after the two companies decided to open source.Isomorphic Labs Currently in internal useAlphaFold3 To accelerate their own drug discovery efforts.

In the past year or so,Isomorphic Labs Established high-profile partnerships with several large pharmaceutical companies. The company in2024 Announced two strategic partnerships with Eli Lilly and Novartis at the beginning of the year, which could potentially lead toIsomorphic Labs Bring Near30 The value in billions of dollars, excluding any potential royalties from future drug sales. Last month, the company stated that it had also expanded the scope of its small-molecule drug discovery agreement with Novartis, adding three additional research projects.

Generate: Biomedicines 

• Leading Asset Technology: AntiTSLPAntibody

• Disease Area: Immunology, Infectious Diseases, and Immuno-Oncology

• Latest News: Collaborating with Novartis to Discover and Develop Protein Therapies 

Generate Biomedicines In2020 After gaining recognition this year, Anima Biotech Inc., as a leader in the field of generative biology, has made remarkable progress in utilizing artificial intelligence to discover and develop innovative new drug candidates. The company's artificial intelligence technology is known asGenerate PlatformIt generates protein sequences in a continuous loop to address specific therapeutic questions, constructs computationally generated sequences into large-scale actual proteins, measures key molecular characteristics and functions of the generated proteins, and conducts learning to drive improvements in the company's engine and each generated molecule.

Since its establishment,Generate AlreadyGenerate The platform has expanded into new models, including bispecific antibodies, enzymes,T Cell adhesives and cell therapy. The company currently has a strong pipeline in the fields of immunology, infectious diseases, and immuno-oncology. Its main asset is a product namedGB-0895 Anti-TSLP Antibody, for the treatment of severe asthma, is currently in1 In the research period.

This company is considered a"Biotech Unicorn" Has Raised a Significant Amount of Funding Since Its Emergence.2023 Year9 In the month, the company obtained2.73 Billion US dollarsC Round of financing — this was the largest private biotechnology financing round of the month — since2020 Since the year, the total funds raised by the company have reached nearly7 Billion USD.

In addition,Generate Has also established high-profile partnerships with some large pharmaceutical companies.2022Year,Generate Collaborate with Amgen to discover and develop protein therapies for five clinical targets across multiple therapeutic areas and modalities. Recently, last year9 Month,Generate Reaching an agreement with Novartis, this is one of the largest biotech deals of the month. The two companies are leveragingGenerate GenerationAI Platform cooperation discovers and develops protein therapies across multiple disease areas.

Latent Labs

• Technology: Designing Therapeutic Proteins

• Business Model: Partner-Driven 

• Latest News:ARound of Financing4000"Million USD $"

Just last month,Latent LabsInA Raised in the round of financing4000 Million USD Later, Becomes the Center of Attention. Coincidentally, the company is also founded bySimon Kohl Founded by him, it is an award-winningAI ModelAlphaFold An important figure in development. However, due toAlphaFold Not intended to create novel proteins from scratch, thusLatent Labs Hope to further create entirely new therapeutic proteins that do not exist in nature based on this foundation.

This method can develop proteins that adapt to specific functions and expand drug targets, as many diseases remain untreatable because natural proteins do not provide the right molecular tools to address them. 

It is worth noting that,Latent Labs It adopts a partner-driven model rather than focusing on developing its own patented candidate drugs. By not restricting its technology to internal projects or exclusive licensing agreements, the company allows a broader range of partners to utilize its...AI Tools, enabling small biotech companies and academic institutions to utilize their technology without significant upfront investment or exclusive agreements.

Relay Therapeutics

• Technology:PI3Kα-Inhibitor

• Major M&A Activities: Acquisition ZebiAI And Its Machine Learning-DEL Technology

• Latest News: In PIPE Secured in the financing round3000 Million USD

Relay Therapeutics TheDynamo The platform integrates a series of computational and experimental methods aimed at drug discovery targeting previously difficult or insufficiently addressed protein targets. To complement its own technology,Relay Return to2021 Acquired inZebiAI And Its Machine Learning-DEL (ML-DEL) A method that can predict potential small molecules binding to the target protein.

Relay The main focus is on strengthening the discovery of small-molecule treatments for tumors and genetic diseases. The company recently advanced its breast cancer candidate drugRLY-2608 Significant progress has been made in this aspect, and the drug is a phosphoinositide.3-Kinase α(PI3Kα) Inhibitors, designed to target and suppressPI3Kα mutant form, thereby avoiding impact on normal enzymes, with the hope of minimizing off-target effects and reducing toxicity.

Last Year 9 Month,RelayInterim data from the second phase of the trial has been released, showing that its candidate drug has exceeded its survival goals. The study tested the candidate drug against Pfizer'sFaslodex(The combination effect of fulvestrant) showed that, in patients who have received extensive treatment,PI3Kα Mutation,HR+/HER2- In patients with metastatic breast cancer, the median progression-free survival is9.2 Months.Relay AstraZenecaTruqap A subgroup of the study served as the trial benchmark, these results suggest that, if approved,RLY-2608 May ultimately challenge AstraZeneca's product.

RelayYu2024 Year1 Month in Private Equity Investment(PIPE) Raised in the financing round3000 "Million USD."

Recursion 

• Leading Asset Technology: Small Molecule Superoxide Scavenger

• Major M&A Activities: With AI-Driven Drug Discovery Companies Exscientia Merge

• Latest News: Lead Drug for Treating Chronic Myocardial Infarction Announced REC-994 Encouraging2 Apex Line Data

AI Drug Discovery Company Recursion The core mission isRecursion Operating System(OS), This is a platform built across multiple technologies that can continuously expand one of the largest proprietary datasets in biology, chemistry, and patient-centered data in the world.

At the same time, the company owns a name called LOWE Large Language Model(LLM), enabling scientists and technicians to query directlyRecursionOS, identify new targets, generate new compounds, and even arrange compounds for synthesis and experimentation.2024 Year6 Month,RecursionAnnouncing that Bayer will becomeLOWE The First Externalbeta Users, for drug discovery and development.

Last year,Recursion Also with another companyAI Pharmaceutical R&D CompanyExscientia Merger, created a company, at the time of the merger, the company was in18 Within months, there is10 Clinical reports are worth looking forward to. This merger also integrates several high-profile partnerships; in addition to the collaboration with Bayer,Recursion Also withGenentech Agreements have been reached in the fields of neuroscience and gastrointestinal oncology, andExscientia Collaborated with Sanofi and Merck in the fields of immunology and oncology.

Recursion Clinical candidate drugs for tumors and rare diseases have been developed so far. Its most advanced assetREC-994 Is an orally bioavailable small molecule superoxide scavenger being developed for the treatment of cerebral cavernous malformations.(CCM)，CompanyYu2024 Year9 Announced the candidate drug in the month2 Encouraging top-line results from the Phase trial.

Recommended Reading